SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review

SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review

Introduction Type 2 diabetes mellitus (T2DM) is an increasing health concern, and diabetic kidney disease (DKD) affects 30–40% of patients with diabetes. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective medications used in the treatment of T2DM, which not only improve glycemic contro...

Full description

Saved in:

Bibliographic Details
Main Authors:	Michał Szczepański, Marcin Kuliga, Mateusz Bajak, Julia Słowik, Julia Inglot, Jadwiga Inglot, Dominik Maciej Feret, Daniel Zapasek, Maciej Mamczur, Damian Sowa
Format:	Article
Language:	English
Published:	Kazimierz Wielki University 2024-12-01
Series:	Journal of Education, Health and Sport
Subjects:	SGLT2 inhibitors type 2 diabetes mellitus chronic kidney disease diabetic kidney disease
Online Access:	https://apcz.umk.pl/JEHS/article/view/56369
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Contrast-induced nephropathy - prevention and treatment
by: Mateusz Bajak, et al.
Published: (2024-11-01)

Genetic causes of short stature in children
by: Jadwiga Inglot, et al.
Published: (2024-12-01)

Infliximab: Pharmacological Properties, Mechanism of Action, and Clinical Applications in the Treatment of Selected Inflammatory Diseases
by: Julia Słowik, et al.
Published: (2024-12-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
by: Angelica Cersosimo, et al.
Published: (2024-10-01)

The Effects of Cannabinoid Compounds on the Endocrine System
by: Julia Inglot, et al.
Published: (2024-12-01)

Metformin From Diabetes Management to Broader Applications in Weight Reduction and Metabolic Health
by: Daniel Zapasek, et al.
Published: (2024-12-01)

The Influence of the Gut Microbiome on the Pathogenesis of Asthma: A Review of Current Research and Therapeutic Options
by: Dominik Maciej Feret, et al.
Published: (2024-12-01)

Sarcoidosis: Pathogenesis, Diagnosis, and Clinical Management
by: Marcin Kuliga, et al.
Published: (2024-12-01)

Neuroplasticity in Depressive Disorders: The Role of BDNF in Linking Pharmacotherapy and Physical Activity
by: Maciej Mamczur, et al.
Published: (2024-12-01)

The association between the utilization of SGLT2 inhibitors and diabetic retinopathy; a systematic review and meta-analysis of cohort studies
by: Shahriar Barkhordari, et al.
Published: (2024-06-01)

Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes
by: Xuehong Li, et al.
Published: (2024-11-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
by: Xiang Xiao, et al.
Published: (2024-12-01)

A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand
by: Natthakan Chitpim, et al.
Published: (2025-01-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

Incidence of hyperkalemia RAASi and SGLT-2i treatment in individuals with diabetic kidney disease: a systematic review and network meta-analysis
by: Yahui Yuan, et al.
Published: (2025-01-01)

A study of SGLT2 inhibitors on levels of plasma atherogenesis biomarkers in diabetes
by: Naveenkumar Nallathambi, et al.
Published: (2024-11-01)

Antihypertensive effects of SGLT2 inhibitors; a letter to the editor on new concepts
by: Rahimeh Eskandarian, et al.
Published: (2024-06-01)

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production
by: Yan Tian, et al.
Published: (2025-12-01)

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01)

Diabetic ketoacidosis induced by SGLT2 inhibitors in acute ischemic stroke: a report of two cases
by: Jin-Heon Jeong
Published: (2024-12-01)

Study of clinical and histopathological factors predicting rapid progression in biopsy-proven type 2 diabetic kidney disease
by: Shilna Muttickal Swaminathan, et al.
Published: (2024-08-01)

Exacerbation of diabetes due to F. Nucleatum LPS-induced SGLT2 overexpression in the renal proximal tubular epithelial cells
by: Aiko Seki, et al.
Published: (2025-01-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

SGLT‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series
by: Wei Qiang, et al.
Published: (2024-09-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

Role of Metformin in Preventing New-Onset Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus
by: Yu-Ling Lin, et al.
Published: (2025-01-01)

Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials
by: Yuxin Zhang, et al.
Published: (2025-01-01)

Safety of SGLT2 Inhibitors and Urinary Tract Infections in Clinical Practice—A Cross-Sectional Study
by: Liana Iordan, et al.
Published: (2024-12-01)

The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives—A Narrative Review
by: Giuseppe Miceli, et al.
Published: (2024-11-01)

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01)

Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis
by: Yunjie Teng, et al.
Published: (2024-12-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Cellular cross-talk drives mesenchymal transdifferentiation in diabetic kidney disease
by: Arunita Chatterjee, et al.
Published: (2025-01-01)

Serum adropin levels as a potential biomarker for predicting diabetic kidney disease progression
by: I-Wen Chen, et al.
Published: (2025-02-01)

Inhibition of sodium‐glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis‐related kidney disease
by: Takuro Nagoya, et al.
Published: (2019-12-01)

SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes
by: Yun Wen, et al.
Published: (2024-12-01)

SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives
by: Cassandra Morciano, et al.
Published: (2024-12-01)

Gender-associated features in diabetic kidney disease
by: S.S. Safarova
Published: (2024-10-01)